Overview

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Objectives - To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. - To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Treatments:
Desvenlafaxine Succinate